|Videos|November 17, 2021
Pharmacist Medication Insights: Hizentra for Primary Immunodeficiency
Author(s)Saro Arakelians, PharmD
Hizentra is indicated for the treatment of primary immunodeficiency in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.
Advertisement
Hizentra is an immune globulin subcutaneous (Human) (IGSC), 20%. It is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Round-Up: Every Most Favored Nation Agreement With the Trump Administration
2
Study Finds Persistent Gaps in Diagnoses for Depression and Chronic Conditions After COVID-19
3
Dato-DXd Granted Priority Review as First-Line Therapy for Metastatic Triple-Negative Breast Cancer
4
Expert: Early Phase 1 Data Shows KTX-1001 Targeting NSD2 Offers Promise for Relapsed/Refractory Multiple Myeloma
5